NL-OMON23842已完成不适用
Efficacy and tolerability of ixazomib, daratumumab and low dose dexamethasone (IDd) followed by ixazomib and daratumumab maintenance therapy until progression for a maximum of 2 years in unfit and frail newly diagnosed multiple myeloma patients; an open-label phase II trial
Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON)0 个研究点目标入组 132 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 132
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Previously untreated patients with a confirmed diagnosis of multiple myeloma according to IMWG criteria (see appendix A);
- •Measurable disease according to the IMWG criteria;
- •(If plasmacytoma is the only measurable parameter, the patient is not allowed to be included in the study, because of difficult response evaluation)
排除标准
- •Non-secretory MM;
- •Plasma cell leukemia;
研究者
相似试验
进行中（未招募）
1 期
Treatment of unfit and frail newly diagnosed multiple myeloma patients with ixazomib, daratumumab and low dose dexamethasone (IDd) followed by ixazomib and daratumumab maintenance therapy until progression for a maximum of 2 years in .How effective is this treatment and how well is it tolerated?MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864Multiple MyelomaEUCTR2016-002600-90-BEHOVON Foundation132
招募中
2 期
Efficacy and tolerability of ixazomib, daratumumab and low dose dexamethasone (IDd) followed by ixazomib and daratumumab maintenance therapy until progression for a maximum of 2 years in unfit and frail newly diagnosed multiple myeloma patients; an open-label phase II trial10035227Multiple MyelomaNL-OMON53051HOVO112
进行中（未招募）
1 期
Treatment of unfit and frail newly diagnosed multiple myeloma patients with ixazomib, daratumumab and low dose dexamethasone (IDd) followed by ixazomib and daratumumab maintenance therapy until progression for a maximum of 2 years in .How effective is this treatment and how well is it tolerated?MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Multiple MyelomaEUCTR2016-002600-90-NLHOVON Foundation132
进行中（未招募）
1 期
Study of Ixazomib + Daratumumab + Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)Relapsed and/or Refractory Multiple MyelomaMedDRA version: 16.1Level: HLTClassification code 10028229Term: Multiple myelomasSystem Organ Class: 100000004851EUCTR2017-003977-32-NLMillennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited60
进行中（未招募）
1 期
Study of Ixazomib + Daratumumab + Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)Relapsed and/or Refractory Multiple MyelomaMedDRA version: 16.1 Level: HLT Classification code 10028229 Term: Multiple myelomas System Organ Class: 100000004851EUCTR2017-003977-32-PLMillennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited60